Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database

Soo Youn Bae, Sei Joong Kim, Jung Sun Lee, Eun Sook Lee, Eun Kyu Kim, Ho Young Park, Young Jin Suh, Hong Kyu Kim, Ji Young You, Seung Pil Jung

Research output: Contribution to journalArticle

Abstract

Purpose: We analyzed the clinicopathologic characteristics and prognosis of pregnancy-associated breast cancer (PABC) according to clinical subtypes to better understand the characteristics of PABC. Methods: A total of 83,792 female patients between the ages of 20 and 49 were enrolled in the Korean Breast Cancer Society Registry database from January 1, 1996 to December 31, 2015. ‘PABC’ is defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Other patients were defined as ‘non-PABC’ patients. Results: In non-PABC patients, luminal A subtype was the most common (50.2%). In PABC patients, TNBC was the most common (40.4%) subtype, while luminal A comprised 21.2% and HER2 subtype comprised 17.3%. There was a significant difference in overall survival (OS). In non-PABC patients, TNBC had the highest HR (HR 2.3, 95% CI 2.1–2.6). In PABC patients, the luminal B subtype (HR+ HER2-high Ki67) had the highest HR at 7.0 (95% CI 1.7–29.1). In multivariate analysis of OS by subtypes, PABC patients had significantly higher HR than non-PABC patients in the HER2 subtype (HR 2.0, 95% CI 1.1–3.7) and luminal B subtype (HR+ HER2-high Ki67) (HR 4.4, 95% CI 1.6–12.3). Conclusion: PABC showed different biologic features than non-PABC. PABC had a particularly poor prognosis in the luminal B (HR+ HER2-highKi67) and HER2 subtypes. To improve the prognosis of PABC, treatment should be considered according to subtype. Development of drugs that can be used during pregnancy is needed.

Original languageEnglish
JournalBreast Cancer Research and Treatment
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Registries
Databases
Breast Neoplasms
Pregnancy
Survival
Second Primary Neoplasms
Multivariate Analysis

Keywords

  • Breast cancer
  • Pregnancy
  • Prognosis
  • Subtype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical subtypes and prognosis of pregnancy-associated breast cancer : results from the Korean Breast Cancer Society Registry database. / Bae, Soo Youn; Kim, Sei Joong; Lee, Jung Sun; Lee, Eun Sook; Kim, Eun Kyu; Park, Ho Young; Suh, Young Jin; Kim, Hong Kyu; You, Ji Young; Jung, Seung Pil.

In: Breast Cancer Research and Treatment, 01.01.2018.

Research output: Contribution to journalArticle

Bae, Soo Youn ; Kim, Sei Joong ; Lee, Jung Sun ; Lee, Eun Sook ; Kim, Eun Kyu ; Park, Ho Young ; Suh, Young Jin ; Kim, Hong Kyu ; You, Ji Young ; Jung, Seung Pil. / Clinical subtypes and prognosis of pregnancy-associated breast cancer : results from the Korean Breast Cancer Society Registry database. In: Breast Cancer Research and Treatment. 2018.
@article{6def494ff231457aaa5675a50d4bbd57,
title = "Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database",
abstract = "Purpose: We analyzed the clinicopathologic characteristics and prognosis of pregnancy-associated breast cancer (PABC) according to clinical subtypes to better understand the characteristics of PABC. Methods: A total of 83,792 female patients between the ages of 20 and 49 were enrolled in the Korean Breast Cancer Society Registry database from January 1, 1996 to December 31, 2015. ‘PABC’ is defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Other patients were defined as ‘non-PABC’ patients. Results: In non-PABC patients, luminal A subtype was the most common (50.2{\%}). In PABC patients, TNBC was the most common (40.4{\%}) subtype, while luminal A comprised 21.2{\%} and HER2 subtype comprised 17.3{\%}. There was a significant difference in overall survival (OS). In non-PABC patients, TNBC had the highest HR (HR 2.3, 95{\%} CI 2.1–2.6). In PABC patients, the luminal B subtype (HR+ HER2-high Ki67) had the highest HR at 7.0 (95{\%} CI 1.7–29.1). In multivariate analysis of OS by subtypes, PABC patients had significantly higher HR than non-PABC patients in the HER2 subtype (HR 2.0, 95{\%} CI 1.1–3.7) and luminal B subtype (HR+ HER2-high Ki67) (HR 4.4, 95{\%} CI 1.6–12.3). Conclusion: PABC showed different biologic features than non-PABC. PABC had a particularly poor prognosis in the luminal B (HR+ HER2-highKi67) and HER2 subtypes. To improve the prognosis of PABC, treatment should be considered according to subtype. Development of drugs that can be used during pregnancy is needed.",
keywords = "Breast cancer, Pregnancy, Prognosis, Subtype",
author = "Bae, {Soo Youn} and Kim, {Sei Joong} and Lee, {Jung Sun} and Lee, {Eun Sook} and Kim, {Eun Kyu} and Park, {Ho Young} and Suh, {Young Jin} and Kim, {Hong Kyu} and You, {Ji Young} and Jung, {Seung Pil}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10549-018-4908-6",
language = "English",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Clinical subtypes and prognosis of pregnancy-associated breast cancer

T2 - results from the Korean Breast Cancer Society Registry database

AU - Bae, Soo Youn

AU - Kim, Sei Joong

AU - Lee, Jung Sun

AU - Lee, Eun Sook

AU - Kim, Eun Kyu

AU - Park, Ho Young

AU - Suh, Young Jin

AU - Kim, Hong Kyu

AU - You, Ji Young

AU - Jung, Seung Pil

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: We analyzed the clinicopathologic characteristics and prognosis of pregnancy-associated breast cancer (PABC) according to clinical subtypes to better understand the characteristics of PABC. Methods: A total of 83,792 female patients between the ages of 20 and 49 were enrolled in the Korean Breast Cancer Society Registry database from January 1, 1996 to December 31, 2015. ‘PABC’ is defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Other patients were defined as ‘non-PABC’ patients. Results: In non-PABC patients, luminal A subtype was the most common (50.2%). In PABC patients, TNBC was the most common (40.4%) subtype, while luminal A comprised 21.2% and HER2 subtype comprised 17.3%. There was a significant difference in overall survival (OS). In non-PABC patients, TNBC had the highest HR (HR 2.3, 95% CI 2.1–2.6). In PABC patients, the luminal B subtype (HR+ HER2-high Ki67) had the highest HR at 7.0 (95% CI 1.7–29.1). In multivariate analysis of OS by subtypes, PABC patients had significantly higher HR than non-PABC patients in the HER2 subtype (HR 2.0, 95% CI 1.1–3.7) and luminal B subtype (HR+ HER2-high Ki67) (HR 4.4, 95% CI 1.6–12.3). Conclusion: PABC showed different biologic features than non-PABC. PABC had a particularly poor prognosis in the luminal B (HR+ HER2-highKi67) and HER2 subtypes. To improve the prognosis of PABC, treatment should be considered according to subtype. Development of drugs that can be used during pregnancy is needed.

AB - Purpose: We analyzed the clinicopathologic characteristics and prognosis of pregnancy-associated breast cancer (PABC) according to clinical subtypes to better understand the characteristics of PABC. Methods: A total of 83,792 female patients between the ages of 20 and 49 were enrolled in the Korean Breast Cancer Society Registry database from January 1, 1996 to December 31, 2015. ‘PABC’ is defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Other patients were defined as ‘non-PABC’ patients. Results: In non-PABC patients, luminal A subtype was the most common (50.2%). In PABC patients, TNBC was the most common (40.4%) subtype, while luminal A comprised 21.2% and HER2 subtype comprised 17.3%. There was a significant difference in overall survival (OS). In non-PABC patients, TNBC had the highest HR (HR 2.3, 95% CI 2.1–2.6). In PABC patients, the luminal B subtype (HR+ HER2-high Ki67) had the highest HR at 7.0 (95% CI 1.7–29.1). In multivariate analysis of OS by subtypes, PABC patients had significantly higher HR than non-PABC patients in the HER2 subtype (HR 2.0, 95% CI 1.1–3.7) and luminal B subtype (HR+ HER2-high Ki67) (HR 4.4, 95% CI 1.6–12.3). Conclusion: PABC showed different biologic features than non-PABC. PABC had a particularly poor prognosis in the luminal B (HR+ HER2-highKi67) and HER2 subtypes. To improve the prognosis of PABC, treatment should be considered according to subtype. Development of drugs that can be used during pregnancy is needed.

KW - Breast cancer

KW - Pregnancy

KW - Prognosis

KW - Subtype

UR - http://www.scopus.com/inward/record.url?scp=85051298546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051298546&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4908-6

DO - 10.1007/s10549-018-4908-6

M3 - Article

C2 - 30088177

AN - SCOPUS:85051298546

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -